Genmab Announces Daratumumab and Ofatumumab Data to Be

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Genmab Announces Daratumumab and Ofatumumab Data to Be Presented at American Society of Hematology Annual Meeting (ASH)

Media Release

  • 10 abstracts on Genmab programs scheduled for presentation at ASH
  • Preliminary data from Phase I  and Phase I/II studies of daratumumab in combination with treatment regimens containing bortezomib or various  immunomodulatory drugs in multiple myeloma
  • Data from Phase III studies of ofatumumab
  • Pre-clinical data on HuMax®-TAC-ADC

Copenhagen, Denmark; November 6, 2014 – Genmab A/S (OMX: GEN) announced today that a total of 10 abstracts for studies of Genmab’s and our collaboration partners’ programs have been accepted for presentation at the 56 th American Society of Hematology (ASH) Annual Meeting and Exposition December 6-9 in San Francisco, California. The abstracts include data on the daratumumab and ofatumumab programs and pre-clinical animal model data with HuMax-TAC-ADC. The abstracts are available on the ASH website at www.hematology.org.

Daratumumab Abstracts to Be Presented
Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma – Oral presentation Sunday, December 7 from 12 Noon to 1:30PM PST

An Open-label, Multicenter, Phase Ib Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma – Oral presentation Sunday, December 7 from 4:30 to 6:30PM PST

Daratumumab, a novel Anti-CD38 Monoclonal Antibody Shows Anti-tumor Activity in CLL and Hampers Leukemia-microenvironment Interactions – Poster presentation, Monday, December 8 from 6:00 to 8:00PM PST

Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79 – Poster presentation, Sunday, December 7 from 6:00 to 8:00PM PST

Anti-leukemic Activity of Daratumumab in Acute Myeloid Leukemia Cells and Patient-Derived Xenografts – Poster presentation, Sunday, December 7 from 6:00 to 8:00PM PST

Modulation of CD38 Expression Levels on Multiple Myeloma Tumor Cells by All-Trans Retinoic Acid Improves the Efficacy of the Anti-CD38 Monoclonal Antibody Daratumumab – Poster presentation, Saturday, December 6 from 5:30 to 7:30 PM PST

Ofatumumab Abstracts to Be Presented
Ofatumumab (OFA) Maintenance Prolongs PFS in Relapsed CLL: PROLONG Study Interim Analysis Results – Oral presentation, Saturday, December 6 from 12 Noon to 1:30PM PST

Ofatumumab (Ofa) vs. Physician’s Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukemia (CLL): Results of the Phase III study OMB114242 - Poster presentation, Monday, December 8 from 6:00 to 8:00PM PST

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD study (OMB110928) – Oral presentation, Monday, December 8 from 4:30 to 6:00PM PST

HuMax-TAC-ADC (ADCT-301) Abstract to Be Presented
Pre-clinical Activity of ADCT-301, a Novel Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies - Poster presentation, Monday, December 8 from 6:00 to 8:00PM PST

Other Abstracts to Be Presented
CD38 Chimeric Antigen Receptor Engineered T Cells as Tools for Immunotherapy of Multiple Myeloma - Poster presentation, Monday, December 8 from 6:00 to 8:00 PM PST

Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells By Combining Therapeutic Antibodies with CD20-Specific Immunoligands Engaging NKG2D or NKp30 - Poster presentation, Saturday, December 6 from 5:30 to 7:30PM PST

About daratumumab
Daratumumab is a human CD38 monoclonal antibody with broad-spectrum killing activity. Daratumumab is in clinical development for multiple myeloma (MM). Daratumumab targets the CD38 molecule which is highly expressed on the surface of multiple myeloma cells. Daratumumab may also have potential in other cancers on which CD38 is expressed, including diffuse large B-cell lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, plasma cell leukemia, acute myeloid leukemia, follicular lymphoma and mantle cell lymphoma.  Daratumumab has been granted Breakthrough Therapy Designation from the US FDA  for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or who are double refractory to a PI and an IMiD.  In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop, manufacture and commercialize daratumumab.

About ofatumumab
Ofatumumab is a human monoclonal antibody which targets an epitope on the CD20 molecule encompassing parts of the small and large extracellular loops 1 . Ofatumumab is being developed under a co-development and collaboration agreement between Genmab and the GlaxoSmithKline group of companies.  Ofatumumab is not licensed anywhere in the world as maintenance therapy in relapsed chronic lymphocytic leukemia (CLL), bulky CLL or relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

About HuMax-TAC-ADC
HuMax-TAC is a high-affinity fully human antibody targeting CD25, a therapeutic target with strong clinical validation. CD25 is expressed on a variety of hematological tumors and shows limited expression on normal tissues, which makes it a very attractive target for antibody-payload approaches. With HuMax-TAC-ADC, we aim to develop a first-in-class antibody-drug conjugate for the potential treatment of CD25-expressing lymphomas and leukemias.  HuMax-TAC-ADC is being developed under an agreement between Genmab and ADC Therapeutics.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.  Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and daratumumab in late stage clinical development for multiple myeloma. Additionally Genmab has a clinical pipeline with both late and early stage programs, and an innovative pre-clinical pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody™ platform which creates effector function enhanced antibodies. Genmab's deep antibody expertise is expected to provide a stream of future product candidates.  Partnering of selected innovative product candidates and technologies is a key focus of Genmab’s strategy and the company has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com .

Contact:          
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo™; the HexaBody logo™; HuMax ® ; HuMax-CD20 ® ; DuoBody ® ; HexaBody™ and UniBody ® . Arzerra ® is a registered trademark of the GSK group of companies.

[1] Teeling et al, J Immunol 2006; 177:362-371

Media Release no. 06
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 0

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 202

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
Disney Springs Hotel Rates Test Holiday Demand Depth

Updated Category News Views 49

A $145 room rate is the sort of holiday bait that gets my attention before the fake snow does. Disney Springs Resort Area Hotels are extending a seasonal offer for stays through Dec. 18, 2026, with bookings open only through Nov. 20. That is a very narrow selling window, and it tells you plenty: these seven independent hotels want to fill rooms during a lucrative but...

Continue Reading
Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 24

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Miami I20 Tests Appetite for Long-Term U.S. Capital

Updated Category News Views 28

Five days in a Miami airport hotel may not sound like the machinery of national investment policy, yet the guest list for the inaugural I20 Summit is serious enough to make capital markets sit up. From December 11 through 15, the Sovereign Wealth Fund Institute plans to bring sovereign funds, pensions, endowments, family offices, business leaders and U.S....

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 89

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 83

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 157

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 42

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
America's Group Adds Swansea to Its UK Auction Map

Updated Category News Views 38

A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring High ROIC Tech Stocks: Key Insights and Analysis

Updated Category News Views 284

Understanding ROIC in Tech Stocks Return on Invested Capital (ROIC) is a vital indicator when evaluating a company's financial performance and investment potential. It reflects how efficiently a firm uses the capital invested by shareholders to generate profits. High ROIC values signal that a company is not only effective in utilizing its resources but may also be poised...

Continue Reading
Join AVITA Medical's Upcoming Investor Webinar Event

Updated Category News Views 141

AVITA Medical Plans Informative Investor Webinar AVITA Medical, Inc. (NASDAQ: RCEL), known for its innovative approaches to acute wound care, is gearing up to host an insightful investor webinar. The CEO, Jim Corbett, alongside CFO, David O'Toole, will lead this engaging session and discuss the latest financial results and strategic business developments. Details of the...

Continue Reading
Labour Government's Budget Aims to Restore Market Stability

Updated Category News Views 138

Introduction to the New Labour Budget The newly formed Labour government has introduced its first budget, aiming to restore confidence in the UK markets. With a focus on substantial tax increases and strategic spending control, this budget seeks to avoid the destabilizing impact seen during Liz Truss's tenure. The measures announced are designed to bolster the economy...

Continue Reading
Beacon Energy to Host Annual General Meeting This December

Updated Category News Views 166

Beacon Energy's Annual General Meeting Update Beacon Energy plc (AIM: BCE, NYSE: BCE) is an oil and gas company dedicated to developing its onshore assets in Germany. Recently, the company confirmed that it is set to hold its Annual General Meeting (AGM) on December 18, 2024. This significant event will be hosted at 55 Athol Street, Douglas, Isle of Man, providing a prime...

Continue Reading
Okeanis Eco Tankers: Key Insights Ahead of Earnings Call

Updated Category News Views 130

Anticipating Okeanis Eco Tankers' Upcoming Earnings Okeanis Eco Tankers (NYSE:ECO) is preparing to release its latest quarterly earnings report soon. Investors and analysts are keenly focused on what this announcement will bring, particularly in terms of earnings expectations and guidance for upcoming quarters. Expected Earnings Report Industry analysts anticipate that...

Continue Reading